Drug
Danirixin clinical trials
Also written GSK1325756.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2017 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses danirixin is read from its arms, and is right about nine times in ten.
Testing it · 11
- Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)TerminatedPhase 2GlaxoSmithKlineNCT03250689Written as Danirixin
- Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2GlaxoSmithKlineNCT03034967Written as Danirixin
- A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)TerminatedPhase 2GlaxoSmithKlineNCT03170232Written as Danirixin 35 mg tablets
- Safety, Tolerability and Clinical Effect of Danirixin in Adults With InfluenzaCompletedPhase 2GlaxoSmithKlineNCT02469298Written as GSK1325756 (Danirixin)
- Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years OldCompletedPhase 1GlaxoSmithKlineNCT01267006Written as GSK1325756
- Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for ExacerbationsCompletedPhase 2GlaxoSmithKlineNCT02130193Written as Danirixin
- Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump InhibitorsCompletedPhase 1GlaxoSmithKlineNCT01209104Written as GSK1325756
- First Time in Human Study With GSK1325756CompletedPhase 1GlaxoSmithKlineNCT01209052Written as GSK1325756
- A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is ReducedCompletedPhase 1GlaxoSmithKlineNCT01453478Written as GSK1325756
- Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT02169583Written as GSK1325756 Solution
- Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface ExpressionCompletedPhase 1GlaxoSmithKlineNCT02201303Written as Danirixin
Given in every arm · 2 — danirixin is usual care beside what is tested
- GSK1325756 Relative Bioavailability Study in Healthy Elderly SubjectsCompletedPhase 1GlaxoSmithKlineNCT03457727Written as Danirixin
- Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With InfluenzaTerminatedPhase 2GlaxoSmithKlineNCT02927431Written as Danirixin 15 mg FBE
Codes
What other systems call danirixin · ClinicalTrials.gg INT006303
- MeSH (NLM) C581951danirixinOne source NLM
- UNII (FDA) R318PGH5VPDANIRIXINConfirmed FDA, NLM, Wikidata
- Wikidata Q27076980danirixinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169874DanirixinOne source FDA
- DrugBank DB11922One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581951 | danirixin | One source NLM |
| UNII (FDA) | R318PGH5VP | DANIRIXIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27076980 | danirixin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169874 | Danirixin | One source FDA |
| DrugBank | DB11922 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.